Highly sensitive detection of the PIK3CA
                H1047R
               mutation in colorectal cancer using a novel PCR-RFLP method by Wan-Ming Li et al.
RESEARCH ARTICLE Open Access
Highly sensitive detection of the
PIK3CAH1047R mutation in colorectal cancer
using a novel PCR-RFLP method
Wan-Ming Li, Ting-Ting Hu, Lin-Lin Zhou, Yi-Ming Feng, Yun-Yi Wang and Jin Fang*
Abstract
Background: The PIK3CAH1047R mutation is considered to be a potential predictive biomarker for EGFR-targeted
therapies. In this study, we developed a novel PCR-PFLP approach to detect the PIK3CAH1047R mutation in high
effectiveness.
Methods: A 126-bp fragment of PIK3CA exon-20 was amplified by PCR, digested with FspI restriction endonuclease
and separated by 3 % agarose gel electrophoresis for the PCR-RFLP analysis. The mutant sequence of the
PIK3CAH1047R was spiked into the corresponding wild-type sequence in decreasing ratios for sensitivity analysis.
Eight-six cases of formalin-fixed paraffin-embedded colorectal cancer (CRC) specimens were subjected to PCR-RFLP
to evaluate the applicability of the method.
Results: The PCR-RFLP method had a capability to detect as litter as 0.4 % of mutation, and revealed 16.3 % of the
PIK3CAH1047R mutation in 86 CRC tissues, which was significantly higher than that discovered by DNA sequencing (9.
3 %). A positive association between the PIK3CAH1047R mutation and the patients’ age was first found, except for the
negative relationship with the degree of tumor differentiation. In addition, the highly sensitive detection of a
combinatorial mutation of PIK3CA, KRAS and BRAF was achieved using individual PCR-RFLP methods.
Conclusions: We developed a sensitive, simple and rapid approach to detect the low-abundance PIK3CAH1047R
mutation in real CRC specimens, providing an effective tool for guiding cancer targeted therapy.
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Background
The phosphatidylinositol 3-kinases (PI3Ks) are a large
family of lipid kinases, and play an important role in
many cellular processes, such as cell survival, prolifera-
tion, and migration [1, 2]. PIK3CA, encoding for the
catalytic subunit p110-alpha of class I PI3Ks, is a mem-
ber of this lipid kinase family. It is reported that mutant
PIK3CA contributes to tumorigenesis through increased
tumor invasion, decreased apoptosis and loss of contact
inhibition [3, 4]. More than 30 % of various human can-
cer types were found to contain mutations in the
PIK3CA gene, and it is frequently mutated in cancers of
the liver, breast, stomach, breast, lung, and colon [5, 6].
Recently, several studies have revealed that PIK3CA
mutations are associated with a negative prediction for
targeted therapy by anti-EGFR MoAb (panitumumab or
cetuximab) [7, 8]. In the case of colorectal cancers
(CRC), apart from KRAS and BRAF, which have been
proven to be significant predictive markers of the anti-
EGFR MoAb response [9], the PIK3CA exon-20
(H1047R) point mutation is likely to a potential predict-
ive biomarker of personalized therapy for CRC [10, 11].
De Roock et al. showed that the PIK3CAH1047R mutation
was associated with a worse outcome compared with
wild-type, with a targeted therapy response rate of
0.0 % versus 36.8 %, respectively [8]. Therefore, the
effective detection of the PIK3CAH1047R mutation is
increasingly important to accurately predict and guide
individualized therapy.
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To date, DNA sequencing is considered to be the gold
standard for gene mutation screening, but it is mainly
limited by low sensitivity (20–30 %) for the clinically low
abundance mutations, resulting in incorrect groupings
and improper clinical therapy [12]. Although the rapidly
developed next-generation sequencing technology pro-
vides increased detection sensitivity (5 %) [13], the ad-
vantages of this technology must be further elicited
before it is routinely used. Other methods, such as
HRM, have a higher sensitivity and less sample contam-
ination, but the requirement for special equipment and
an additional sequencing confirmation step limit their
universal application in clinical settings [14, 15]. Digital
PCR has the potential to offer more sensitive and con-
siderably more reproducible clinical methods, but is as
susceptible to upstream errors associated with factors
such as sampling and extraction, and also suffers system-
atic bias [16]. Thus, there is an urgent need to develop a
method that possesses higher detection efficiency and is
suited to routine usage in the laboratory to screen for
low-abundance mutations.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis is a widely applied
method to detect gene mutations, which allows distin-
guishing mutant-type and wild-type sequences via
destructing or generating enzyme restriction sites
through PCR and subsequent electrophoresis separ-
ation of differential fragments [17]. Compared to other
methods, PCR-RFLP offers a simple operation, higher
sensitivity and reproducibility, and no complex equip-
ment requirements [18, 19]. For KRAS exon-2 muta-
tions, the sensitivity of the PCR-RFLP method was at
least 0.1 % [20]. More importantly, it is preferentially
suitable to detect point mutations [21].
For CRC, RFLP methods have been used for the detec-
tion of targeted therapy-related KRAS and BRAF gene
mutations, and the corresponding KRAS mutation assay
kit is commercially available [20, 22]; however, no PCR-
RFLP method has been developed for PIK3CAH1047R.
Several clinical trials and retrospective studies have sug-
gested that the combinatorial detection of KRAS and
BRAF mutations could increase positive mutation detec-
tion and therefore improve therapy response rates [23].
However, recent research showed that some patients
carrying wild-type KRAS and BRAF still do not respond
to anti-EGFR MoAbs, among which PIK3CAH1047R mu-
tation carriers were found [24, 25]. Therefore, the com-
binatorial detection of these three gene mutations might
increase the response rates. Tian et al. analyzed KRAS,
BRAF and PIK3CA mutations in 381 CRC samples in
combination, achieving improved treatment classifica-
tion and increased response rates [26]. In addition, the
current evidence about relationship of PIK3CA mutation
and the targeted therapeutic effect is mostly dependent
on the relatively low sensitivity methods, such as direct
sequencing, which may result in inaccurate information
[27, 28]. Accordingly, in this study, we developed a spe-
cific, fast and simple PCR-RFLP method for detecting
low-abundance PIK3CAH1047R mutations by creating an
FspI restriction endonuclease recognition site to distin-
guish wild- and mutant-type PIK3CAH1047R. In sensitiv-
ity studies, the PCR-RFLP method presented the
capability to detect as little as 0.4 % of the mutant-type
fragment in the presence of the wild-type fragment. In
86 paraffin-embedded CRC tissues, the method could
detect at least 1.5 % of the PIK3CAH1047R mutation,
which was far below that of direct sequencing, and stat-
istical analysis revealed that the PIK3CAH1047R mutation
was associated with patients’ age and tumor differenti-
ation. To explore the possibility of detecting multi-gene
mutations in combination using PCR-RFLP, the muta-
tions of three target-EGFR genes, including KRAS, BRAF




The human colorectal cancer cell lines LoVo, SW620,
LS174T, HT29, HCT-8 and Colo205 were maintained
in RPMI1640 containing 10 % fetal bovine serum
(FBS, Invitrogen, Carlsbad, CA, USA) and 100 units/
ml penicillin-streptomycin (Sigma-Aldrich, St Louis,
MO, USA), and the human colorectal cancer cell lines RKO,
CL187, CX-1 and CloneA were maintained in high-glucose
DMEM containing 100 units/mL penicillin-streptomycin
and 10 % FBS. All of the cells were cultured at 37 °C under
a 5 % CO2 atmosphere. LoVo and SW620 cells were known
to be wild-type for PIK3CAH1047R, while LS174T and RKO
cells possessed heterozygous mutations [29].
Clinical samples
A total of 86 formalin-fixed paraffin-embedded (FFPE)
tissue sections (5 μm) from CRC patients were supplied
by China Medical University (Shenyang, China). The
study was approved by the ethics committee of China
Medical University and all of the patients who pro-
vided tumor samples provided written informed con-
sent. The patients’ characteristics were collected from
the 86 CRC patients, including age, tumor differenti-
ation, gender, tumor size, tumor location, Dukes stage
and lymph node status.
Genomic DNA extraction and PCR-RFLP analysis
Genomic DNA (gDNA) was extracted from the human
colorectal cancer cell lines (1 × 106 cells) using the Gen-
omic DNA Purification Kit (Promega, US) according to
the manufacturer’s instructions. All DNA templates were
eluted with 40 μl ddH2O and stored at −20 °C until use.
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The purity and concentration of extracted DNA were
determined by spectrophotometry (NanoDrop 2000,
Thermo Fisher Scientific Inc., USA). The DNA samples
with absorption ratios of 260/280 nm greater than 1.8
were for subsequent analyses. Subsequently, PCR ampli-
fication was performed using 50 ng of gDNA as template
for the analysis of PIK3CAH1047R mutation statuses.
The 126-bp fragment of the PIK3CA gene covering
exon-20 sequences containing the H1047R mutation site
is shown in Fig. 1. The PCR designed primers used were:
forward, 5′-GGAGTATTTCATGAAACAAATGAATGA
TGCG-3′ (mismatched nucleotide is underlined), and
reverse, 5′-GAGCTTTCATTTTCTCAGTTATCTT-3′.
The mismatch forward primer harbored one mis-
matched site (a→G, Fig. 1, shown in red) to introduce a
new TGCGCA sequence for the FspI restriction endo-
nuclease recognition site. In the wild-type PIK3CA
exon-20, the 126-bp fragment could be digested into 96-
and 30-bp fragments. In contrast, PIK3CAH1047R mutant
alleles were not cleaved due to the substitution of CAT
to CGT, resulting in the loss of the FspI-recognized site.
The PCR reaction was performed using the following
cycling conditions: 94 °C for 45 s, 60 °C for 45 s, and
72 °C for 45 s, 30 cycles. The predicted PCR product
size was 126 bp and confirmed by electrophoresis in 3 %
agarose gel containing ethidum bromide. Typically, 2 μl
of 126-bp PCR products of PIK3CA were digested with
1 unit of restriction endonuclease FspI in 10 μl at 37 °C
for 10 min. The DNA fragments were analyzed by 3 %
agarose gel electrophoresis.
Detection specificity of the PCR-RFLP method
In addition to the H1047R (CAT→CGT) mutation,
PIK3CA exon-20 may clinically harbor the H1047L
mutation (CAT→CTT) [8]. To examine whether the
PIK3CAH1047L mutation could also be resolved by our
method, we synthesized the 126-bp sequence containing
the H1047L mutant sequence. In addition, the sequences
containing the wild-type exon-20 (CAT) and PIK3-
CAH1047R mutant (CGT) were also synthesized. These
synthesized DNAs were amplified by PCR, digested with
FspI, and then electrophoresed on a 3 % agarose gel.
Detection sensitivity of the PCR-RFLP method
To perform the sensitivity analysis, we obtained wild-
type and homozygous mutant-type model sequences by
separating heterozygous mutation-type PIK3CAH1047R
derived from the LS174T cells’ genome using TA clon-
ing. Firstly, the LS174T cells’ 126-bp PCR product was
cloned into the TA vector using the TA cloning kit
(Takara, Japan). Ten bacterial clones were selected and
their plasmids were extracted using the QIAGEN Plas-
mid Mini kit (QIAGEN, Germany) according to the
manufacturer’s instructions. After their inserts were se-
quenced, the homozygous mutant plasmid containing
the PIK3CA gene was mixed with the wild-type plasmid
at the decreasing ratios of 1:1, 1:2, 1:4, 1:16, 1:32, 1:64,
1:128, 1:256, and 1:512, respectively. Subsequently, the
mixed plasmid was subjected to PCR-RFLP analysis.
GDNA extraction from FFPE tissue and mutation
detection
FFPE tumor blocks were cut into 5-μm sections and the
sections with tumor area more than 70 % were dissected
for the study. For gDNA extraction, one 5-μm thick sec-
tion was used for each case. GDNA was extracted from
FFPE tissue samples using the FFPE DNA Kit (OMEGA,
USA) according to the manufacturer’s instructions. All
DNA templates were eluted with 20 μl ddH2O and
stored at −20 °C until use.
Fig. 1 The nucleotide sequence design for the detection of the PIK3CAH1047R mutation by PCR-RFLP. A 126-bp fragment covering PIK3CA exon-20
was chosen from the human genome for PCR amplification. Primer sequences are highlighted in blue. The forward primer sequence harbors one
mismatched site (a→ G, shown in red) to creating a new TGCGCA sequence for the FspI restriction endonuclease recognition site
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In order to investigate the applicability of our PCR-
RFLP method, we first detected the PIK3CA gene
mutation status in 86 FFPE CRC tissue sections. The
wild-type PIK3CA exon-20 of the section was cleaved
into two fragments of 96- and 30-bp, while the mu-
tant type remained intact (126 bp). To explore the
possibility of detecting CRC targeted therapy-related
genes in combination, six samples were chosen to fur-
ther detect the KRAS and BRAF mutant status by the
PCR-RFLP methods. The primers were synthesized by
Sangon Biotechnology Co. Ltd. (Shanghai, China) ac-
cording to previous reports [30, 31]:




After amplification, the fragment of 107 bp was
digested by MvaI. The wild-type KRAS exon-2 allele
were cleaved into two fragments of 77- and 30-bp, while
the mutant type remained intact (107 bp).
For BRAF (224 bp)
Forward: 5′-TCATAATGCTTGCTGATAGGA-3′.
Reverse: 5′-GGCCAAAAATTTAATCAGTGGA-3′.
After amplification, the fragment of 224 bp was
digested by TspI. The wild-type BRAF exon-15 allele
were cleaved into three fragments of 124-, 87- and 13-
bp, while the mutant type yielded only two fragments of
211- and 13-bp.
Sequencing
To confirm the PCR-RFLP results, sequencing analysis
was performed in all samples. All PCR products of
the PIK3CA, KRAS and BRAF genes were directly se-
quenced to confirm the mutation status using ABI
3730xl DNA Analyzer (Sangon Biotechnology Co.
Ltd., Shanghai, China).
For the samples that showed a mutation band in agar-
ose gel electrophoresis but were not detectable by direct
sequencing, clone sequencing was performed by the TA
cloning kit.
Statistical analysis
Statistical analysis was carried out using IBM SPSS 20.0
(IBM Corporation, Armonk, NY, USA). Significant dif-
ferences between groups were assessed using the χ2 test
considering the P value as obtained by Fisher’s exact test.
A P value of less than 0.05 was considered statistically
significant differences.
Results
Establishment of PCR-RFLP method for the detection of
PIK3CAH1047R
We chose the PIK3CA gene 126-bp fragment containing
the H1047R mutation site and introduced a new
TGCGCA sequence for an FspI restriction endonuclease
recognition site by designing a specific mismatch primer
to substitute a with G (Fig. 1). The mutant and wild-type
sequences are distinguishable based on the difference in
size and number of the endonuclease-digested fragment,
as the wild-type fragments were 96 and 30 bp, while the
mutant fragment was 126 bp. First, we used the PCR-
RFLP method to detect CRC cell lines with a known
PIK3CA gene status. As shown in Fig. 2a, LoVo and
SW620 presented in two enzyme-digested fragments
with sizes of 96 and 30 bp, revealing the wild-type
PIK3CA; while LS174T and RKO showed two fragments
96- and 30-bp coexisting with a126-bp fragment, indi-
cating the heterozygous PIK3CAH1047R. All of these re-
sults are consistent with previous reports [30].
To further study the applicability of the PCR-RFLP
method, we used this method to detect six CRC cell
lines whose PIK3CA gene status was not reported. Fig. 2b
(top) shows that CloneA, HCT-8, CX-1, Colo205 and
HT29 cells were cleaved into two fragments with sizes
of 96 and 30 bp, which indicated that there were no
PIK3CAH1047R mutations. For CL187 cells, a 126-bp
fragment besides 96- and 30-bp fragments was detected,
indicating the heterozygous-type PIK3CAH1047R. The re-
sults from PCR-RFLP used to detect the PIK3CA status
in six CRC cell lines were completely consistent with
those obtained by direct sequencing (Fig. 2b, bottom).
Specificity and sensitivity of the PCR-RFLP method
In order to evaluate the specificity of this method, we
synthesized three sequences for detection, including two
sequences with clinically present PIK3CA exon-20 muta-
tion patterns (CGT and CTT) and one with a wild-type
pattern (CAT). As shown in Fig. 3a, the sequence
containing CAT showed two fragments (96 and 30 bp),
indicating wild-type PIK3CA; while the sequences con-
taining CGT or CTT showed a 126 bp fragment, even
after the digestion of FspI, indicating the mutant-type
PIK3CA.
To assess the sensitivity of the method, we constructed
the plasmids carrying the 126-bp fragment of wild-type
and homozygous mutant-type PIK3CA and diluted the
homozygous mutant plasmid in increasing concentra-
tions of the wild-type plasmid to mimic tumor hetero-
geneity. As shown in Fig. 3b (top), the 126-bp fragment
band representing the PIK3CAH1047R mutation gradually
decreased with decreasing proportions of the mutant se-
quence, but it was still detectable, even at mutation con-
centrations as low as 1:256, indicating that the sensitivity
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of our PCR-RFLP method was approximately 0.4 %. In
contrast, DNA sequencing was not able to detect the
PIK3CAH1047R mutation when present at approximately
25 % (1:4) of the total mixture, suggesting that its detec-
tion sensitivity was approximately 25 % (Fig. 3b,
bottom).
Detection of mutant PIK3CAH1047R in clinical CRC samples
In order to investigate the clinical applicability of the
PCR-RFLP method, 86 FFPE tissue sections from
CRC patients were analyzed. As a result, the PCR-
RFLP method identified 16.5 % PIK3CAH1047R muta-
tion, higher than the frequency identified by DNA se-
quencing (8, 9.3 %), among which there were six
PIK3CAH1047R mutant cases that failed to be detected
by DNA sequencing. To determine the accuracy of
our method, these six CRC cases were further
analyzed by clone sequencing. Three representative
results are shown in Fig. 4, and revealed the method’s
capability to detect at least 1.5 % of the PIK3-
CAH1047R mutation in CRC specimens, which was far
below that of direct sequencing.
We further explored the correlation between the CRC pa-
tients’ clinicopathological data and the mutation status of
the PIK3CAH1047R. Statistical analysis of the PCR-RFLP re-
sults revealed that the PIK3CAH1047R mutation was not sig-
nificantly associated with gender, tumor size, tumor
location, Dukes stage and lymph node status (Table 1).
However, levels of the PIK3CAH1047R mutation were signifi-
cantly higher in patients who were older than 60 years in
comparison with patients ≤60 years of age (24.5 vs. 5.4 %,
P = 0.018). Direct sequencing did not reveal the relationship
between the PIK3CAH1047R mutation and age. In addition,
the PIK3CAH1047R mutation was negatively associated with
Fig. 2 Detection of the PIK3CAH1047R mutation in CRC cell lines using PCR-RFLP. a: Detection of four CRC cell lines with known PIK3CA gene status
using PCR-RFLP. The fragment of 126-bp was amplified from the cells’ gDNA, digested with FspI, and then electrophoresed in a 3 % agarose gel.
The FspI digestion of wild-type PIK3CA yields two bands of 96- and 30-bp, while the mutant-type remains intact (126 bp). b: The detection of six
CRC cell lines with unknown PIK3CA gene status by PCR-RFLP (top) and direct sequencing (bottom). M: DL500 DNA marker
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the degree of differentiation by both PCR-RFLP and direct
sequencing method.* statistically significant (p < 0.05)
Detection of the KRAS, BRAF and PIK3CA mutations in
CRC specimens using the PCR-RFLP method
KRAS, BRAF and PIK3CA are considered to have nega-
tive effects on the response to anti-EGFR MoAbs in
CRC. To investigate the possibility of detecting three
gene mutations by the PCR-RFLP method, six of 86 case
samples were analyzed. The PCR-RFLP electrophoresis
results are shown in Fig. 5. For PIK3CA, 96 and 30-bp
fragments were detected in all specimens, while an extra
band at 126-bp was clearly detected in specimens 2 and
3, suggesting they carried PIK3CA mutations. For KRAS,
specimens 1 and 2 had a 107-bp fragment as well as 77-
and 30-bp fragments, suggesting the mutant-type of
KRAS. For BRAF, in addition to an extra band at 211-bp
in specimen 5, the other specimens had 124- and 87- bp
fragments, suggesting only the specimen 5 contained
BRAF mutations. The mutation status of KRAS, BRAF
and PIK3CA are summarized in Table 2 (WT: wild-type,
M: mutant-type).
Discussion
CRC is one of the most common human malignant dis-
eases and is a leading cause of cancer-related deaths
worldwide. Metastases are the major cause of death in
CRC patients [32]. Recently, targeted therapies against
EGFR, such as cetuximab and panitumumab, have im-
proved the survival of patients with metastatic CRC
(mCRC) [33]. However, less than 20 % of unselected
mCRC patients can truly benefit from the anti-EGFR
MoAb treatment [34], highlighting the need to deter-
mine those who are more likely to obtain a clinical
Fig. 3 a: Detection specificity of PCR-RFLP. Synthetic oligonucleotide sequences containing wild-type PIK3CA (CAT) and mutant-type PIK3CA (CGT
or CTT) were subjected to PCR-RFLP. b: Detection sensitivity of PCR-RFLP. The PIK3CAH1047R mutant plasmid was spiked into wild-type plasmid at
different ratios, and analyzed by PCR-RFLP method (top) and direct sequencing (bottom). M: DL500 DNA marker
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benefit from this targeted therapy. KRAS is the first gene
proven to be a predictive biomarker for resistance to the
anti-EGFR MoAb treatment, and BRAF has also been
demonstrated to be a response predictor [35]. Recently,
active PIK3CA mutations were found to be able to pre-
dict resistance to anti-EGFR MoAbs. There are two
major mutational hotspots in exons 9 (E542K, E545K)
and 20 (H1047R) of the PIK3CA gene, and recent stud-
ies have suggested that the PIK3CAH1047R mutation had
a closer relationship with anti-EGFR MoAb treatment
[10]. Thus, the accurate identification of the PIK3-
CAH1047R mutation status is very crucial for guiding per-
sonalized therapy.
To effectively detect the PIK3CAH1047R mutation sta-
tus, we developed a novel PCR-RFLP method by creating
an FspI restriction site. The results showed that the
PCR-RFLP method could distinguish the wild-type and
mutant-type PIK3CAH1047R with complete agreement
with the results obtained by DNA sequencing in differ-
ent CRC cell lines. The specificity of the method was
verified by the analysis of various patterns of the PIK3-
CAH1047 mutation, and its high detection sensitivity was
demonstrated using various quantities of mutation frag-
ments spiked into wild-type fragments, achieving a de-
tection limit as low as 0.4 %, which is significantly
superior to direct sequencing (25 %). Current data in
clinical trials show that not all patients grouped as
wild-type for defined genes benefit from molecular
targeted therapies [36]. There are several reasons for
it, such as the presence of other undefined gene alter-
ations [37, 38], but it is possible that the employed
methods with the limited sensitivity may fail to detect
the low-abundance mutations, resulting in incorrect
classifications. Molinari et al. reported that compared
with direct sequencing, 13 additional KRAS mutations
were identified using highly sensitive methods, which all
were non-responsive to anti-EGFR therapies [39]. In this
study, the PIK3CAH1047R mutation in 86 patients was ana-
lyzed by PCR-RFLP. As a result, we revealed the PIK3-
CAH1047R mutation in 16.3 % of the CRC samples and this
ratio is significantly higher than the result we obtained
using direct sequencing (9.3 %), and the lowest mutation
was 1.5 %. The results demonstrated that our method
could detect low-abundance PIK3CAH1047R mutations and
thus offer accurate guidance for personalized treatment.
In addition, the detection sensitivity is expected to in-
crease further using PAGE electrophoresis-based silver
staining instead of EB staining [20].
The results of the analysis of clinicopathological char-
acteristics from 86 CRC tissues revealed a significant
Fig. 4 Three representative detection results of PCR-RFLP and clone sequencing for CRC FFPE samples. The mutant bands in PCR-RFLP electrophotograms
are indicated by the red arrows. The mutant sits of PIK3CAH1047R in sequencing results were indicated by the black arrows. M: DL500 DNA marker
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correlation between the PIK3CAH1047R mutation and the
patient’s age. Patients over 60 years of age tend to show
significantly more PIK3CAH1047R mutations than pa-
tients under 60 years of age (24.5 vs. 5.4 %, P = 0.018).
To the best of our knowledge, this is the first report to
reveal the significant association between the PIK3-
CAH1047R mutation and the patient’s age. This may
possibly be due to the high detection sensitivity of the
PCR-RFLP method because there was no consistent sta-
tistically significant difference found by direct sequen-
cing. This result further suggests that a detection
method that can resolve low abundance mutations might
provide a better understanding of the clinical signifi-
cance of a given gene mutation. Some previous studies
found that the PIK3CAH1047R mutation is a late event of
CRC progression [7]. Additionally, according to the
tumorigenesis theory, older patients tend to accumulate
more types of gene mutations [40]. Because older pa-
tients possibly encounter more PIK3CAH1047R mutations
and do not respond to targeted therapy, an improved
prognosis might be achieved by the preferential attention
of the patient subpopulation at the early stage of CRC or
below 60 years in clinically targeted therapy. Of course,
much more data from clinical settings is needed to verify
this conclusion. In addition, statistical analysis showed
that patients with poorly differentiated tumors are much
more likely to have the PIK3CAH1047R mutation (poor
52.6 % vs. moderate/well 6.0 %, P = 0.000), which is in
agreement with a recent report [41]. Other clinicopatho-
logical characters, such as Dukes stage, tumor size,
tumor location, gender, and lymph node status showed
no relationship with the PIK3CAH1047R mutation.
In CRC, KRAS and BRAF mutations have been proven
to be predictors of the therapeutic efficiency of anti-
EGFR therapy. In 2010, De Roock and co-workers [8]
demonstrated that the PIK3CAH1047R mutation might be
a new potential response predictor after KRAS and
BRAF for resistance to anti-EGFR mAbs. However, until
now, the clinical significance of PIK3CA mutations in
terms of the prediction of the response to anti-EGFR
therapy still remains incompletely understood, partly
due to the lack of highly effective approaches for detect-
ing related gene mutations in combination [42]. To ex-
plore whether our PIK3CAH1047R-specific PCR-RFLP can
be utilized together with the reported PCR-RFLP
methods for KRAS and BRAF, the three gene mutations
Table 1 Clinicopathological characteristics and PIK3CAH1047R mutation status in 86 CRC cases
Category Total (n) Direct sequencing PCR-RFLP
Mutation (%) P-value Mutation (%) P-value
Number of patients 86 8 (9.3) 14 (16.3)
Age (years) 0.145 0.018*
>60 49 7 (14.3) 12 (24.5)
≤60 37 1 (2.7) 2 (5.4)
Gender 0.275 0.498
Male 53 3 (5.7) 7 (13.2)
Female 33 5 (15.2) 7 (21.2)
Tumor size 0.924 0.702
>5 cm 47 5 (10.6) 7 (14.9)
≤5 cm 39 3 (7.7) 7 (17.9)
Tumor location 0.428 0.564
Colon 37 5 (13.5) 7 (18.9)
Rectum 49 3 (6.1) 7 (14.3)
Tumor differentiation 0.001* < 0.0001*
Well or Moderate 67 2 (3.0) 4 (6.0)
Poor 19 6 (31.6) 10 (52.6)
Dukes’ stage 1.000 1.000
A + B 60 6 (10) 10 (16.7)
C + D 26 2 (7.7) 4 (15.4)
Lymph node metastasis 0.603 0.708
+ 34 2 (5.9) 4 (11.8)
− 69 6 (8.7) 10 (14.5)
*Statistically significant (p < 0.05)
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existing in six CRC specimens were analyzed in combin-
ation by individual PCR-RFLP. The results showed that
four specimens, except for specimens 4 and 6, carried
mutations in different genes, which all were confirmed
by DNA sequencing (data not shown), indicating that
the PCR-RFLP method is able to accurately detect
multi-gene mutations in combination. Like other re-
searchers, we also found that either PIK3CA or BRAF
were present in some wild-type KRAS specimens, such
as PIK3CA in specimen 3 and BRAF in specimen 5, sug-
gesting that it is necessary in clinical practice to investi-
gate the state of the other two genes in KRAS wild-type
patients. In addition, several previous reports demon-
strated that KRAS and BRAF are mutually exclusive in
CRCs [43, 44]. In our study, we also did not find their
co-existence, but the concomitant mutation in KRAS
and PIK3CA was detected in specimen 2. Nevertheless,
their effect on the response to targeted treatment still
needs to be verified further. All of the mutations de-
tected by PCR-RFLP were confirmed by direct sequen-
cing except for PIK3CA in specimen 3, which was
verified by clone sequencing later and displayed a lower
mutant frequency of 2 %. Notably, this PIK3CA was the
only detectable mutation in the specimen, which sug-
gested that a combinatorial PCR-RFLP strategy with
high sensitivity may provide more accurate information
to understand the clinical significance of gene mutations
in spite of limited specimen involvement.
Fig. 5 Detection of PIK3CA, KRAS and BRAF mutations by individual PCR-RFLP methods in CRC samples. a: Detection of the PIK3CA mutation using
our PCR-RFLP. b: Detection of the KRAS mutation using PCR-RFLP. A 107-bp fragment of KRAS was amplified, followed by digestion with MvaI and
analysis by 3 % agarose gel electrophoresis. The MvaI digestion of wild-type KRAS yielded two 77- and 30-bp bands, while the mutant-type
remained intact (107 bp). c: Detection of the BRAF mutation using PCR-RFLP. A 224-bp fragment of BRAF was amplified, and followed by digestion
with TspRI and analysis by 3 % agarose gel electrophoresis. The TspRI digestion of wild-type BRAF yielded three 124-, 87- and 13-bp bands, while
the mutant-type yielded two 211- and 13-bp bands. M: DL500 DNA marker
Table 2 Gene status in different CRC FFPE samples by PCR-RFLP
method
Sample PIK3CA KRAS BRAF
1 WT M WT
2 M M WT
3 M WT WT
4 WT WT WT
5 WT WT M
6 WT WT WT
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Conclusions
In summary, we developed a novel PCR-RFLP method
to detect the PIK3CAH1047R mutation by creating an FspI
restriction endonuclease recognition site. This method is
able to resolve wild-type and mutant-type PIK3CAH1047R
with high specificity and sensitivity, allowing the low
abundance mutation of 0.4 % to be detected. Addition-
ally, this method has several advantages over other
methods, such as simple operation and suitability in a
routine laboratory. Using this method, 86 cases of CRC
specimens were detected with high efficiency, with an
excessively positive rate of PIK3CAH1047R mutations rela-
tive to that using DNA sequencing. Based on this, a
positive correlation between the PIK3CAH1047R mutation
and the patient’s age was found, which might be helpful
in guiding targeted therapy. In addition, the approach
was combined with PCR-RFLP methods for KRAS and
BRAF together and achieved high sensitivity and the ac-
curate detection of multiple gene mutations in parallel
for CRC tissues. Overall, this method could become a
promising tool for guiding personalized tumor therapy
and exploring the clinical applicability of the PIK3-
CAH1047R mutation.
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